Swiss National Bank Sells 77,600 Shares of Amgen Inc. $AMGN

Key Points

• Swiss National Bank reduced its Amgen stake by 4.8%, selling 77,600 shares and holding 1,549,933 shares (about 0.29% of the company) valued at roughly $437.4 million.
• Amgen beat quarterly expectations with EPS $5.29 vs. $4.76 and revenue of $9.87 billion (up 8.6% YoY), and set FY2026 EPS guidance of 21.600–23.000 while analysts expect about 20.62 EPS.
• The company declared a quarterly dividend of $2.52 per share (annualized $10.08, ~2.7% yield), and the stock has a MarketBeat consensus rating of Hold with a $354.17 target price.

Swiss National Bank lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,549,933 shares of the medical research company's stock after selling 77,600 shares during the quarter. Swiss National Bank owned about 0.29% of Amgen worth $437,391,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Brighton Jones LLC raised its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC boosted its position in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock valued at $331,000 after buying an additional 114 shares during the last quarter. Schnieders Capital Management LLC. grew its holdings in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock worth $7,220,000 after buying an additional 5,853 shares in the last quarter. Vestmark Advisory Solutions Inc. raised its position in Amgen by 373.3% in the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 4,842 shares of the medical research company's stock valued at $1,352,000 after buying an additional 3,819 shares during the last quarter. Finally, Legacy Investment Solutions LLC purchased a new stake in Amgen in the 2nd quarter valued at $27,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

NASDAQ AMGN opened at $369.53 on Monday. The company has a market capitalization of $199.20 billion, a PE ratio of 25.97, a price-to-earnings-growth ratio of 3.67 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a 50-day simple moving average of $353.26 and a 200 day simple moving average of $322.80.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts' consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analysts' expectations of $9.46 billion. During the same period in the previous year, the company earned $5.31 earnings per share. The company's quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio is 70.84%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Mizuho lifted their price objective on shares of Amgen from $280.00 to $295.00 and gave the stock an "outperform" rating in a report on Tuesday, February 10th. HSBC reissued a "buy" rating and set a $425.00 price target on shares of Amgen in a research report on Wednesday, December 10th. Wall Street Zen cut shares of Amgen from a "buy" rating to a "hold" rating in a report on Saturday, February 21st. TD Cowen reiterated a "buy" rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, BMO Capital Markets lifted their target price on shares of Amgen from $335.00 to $372.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $354.17.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.